Loading company…
Riskpilot
← Back to search
Sign in
Get full access
MA Pharma Consulting ApS
APS
Dissolved
CVR 44558076
Præstejorden 18
All other professional, scientific and technical activities n.e.c. · NACE 7499
Est. 2024
2 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 329K
EBITDA margin
27.4%
Equity ratio
61.7%
Financial strength
Net profit 2024
DKK 70K
2 employees
EBITDA — year on year
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2024
Key figures
Annual report 2024
Revenue
DKK 329K
—
EBITDA
DKK 90K
—
Net profit
DKK 70K
—
Total assets
DKK 177K
—
Equity
DKK 110K
—
Employees
2
—
Company information
Legal name
MA Pharma Consulting ApS
CVR number
44558076
Legal form
Anpartsselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
3. januar 2024
Share capital
DKK 40.000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 direktører.
Contact
Address
Præstejorden 18
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in All other professional, scientific and technical activities n.e.c.
Companies in Rudersdal
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2024
Income statement
DKK thousands
Item
2024
Revenue
329
Staff expenses
-239
EBITDA
90
Depreciation & amort.
-0
EBIT
90
Net financials
0
Profit before tax
90
Tax
21
Net profit
70
Balance sheet
DKK thousands
Item
2024
Total assets
177
Equity
110
Long-term debt
0
Short-term debt
68
Total debt
68
Financial ratios
5-year trend
EBITDA margin
27.4%
This company
15.8%
Market median
+73% vs market
2024
2024
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
2024
2024
Return on equity
63.5%
This company
18.4%
Market median
+245% vs market
2024
2024
Net profit margin
21.1%
This company
8.1%
Market median
+160% vs market
2024
2024
Asset turnover
1.85×
This company
1.12×
Market median
+65% vs market
2024
2024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-03 – 2024-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (2)
MH
Marianne Holst
Chief Executive Officer
Chief Executive Officer
2024 – 2025
AK
Anne Kræmmer
Management
Management
2024 – 2025
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Marianne Holst og Anne Kræmmer Holding ApS
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of MA Pharma Consulting ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Marianne Holst
Chief Executive Officer
0 companies
Anne Kræmmer
Management
0 companies